TY - JOUR AU - Babey, H. AU - Quere, G. AU - Descourt, R. AU - Calloch, R. AU - Lanfranco, L. AU - Nousbaum, J. B. PY - 2018 DA - 2018// TI - Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review JO - Expert Rev Anticancer Ther VL - 18 UR - https://doi.org/10.1080/14737140.2018.1499468 DO - 10.1080/14737140.2018.1499468 ID - Babey2018 ER - TY - JOUR AU - Hodi, F. S. AU - O'Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Ferris, R. L. AU - Blumenschein, G. AU - Fayette, J. AU - Guigay, J. AU - Colevas, A. D. AU - Licitra, L. PY - 2016 DA - 2016// TI - Nivolumab for recurrent squamous-cell carcinoma of the head and neck JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1602252 DO - 10.1056/NEJMoa1602252 ID - Ferris2016 ER - TY - JOUR AU - Bellmunt, J. AU - Wit, R. AU - Vaughn, D. J. AU - Fradet, Y. AU - Lee, J. L. AU - Fong, L. PY - 2017 DA - 2017// TI - Pembrolizumab as second-line therapy for advanced urothelial carcinoma JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613683 DO - 10.1056/NEJMoa1613683 ID - Bellmunt2017 ER - TY - JOUR AU - Verma, V. AU - Sprave, T. AU - Haque, W. AU - Simone, C. B. AU - Chang, J. Y. AU - Welsh, J. W. PY - 2018 DA - 2018// TI - A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0442-7 DO - 10.1186/s40425-018-0442-7 ID - Verma2018 ER - TY - JOUR AU - Barlesi, F. AU - Vansteenkiste, J. AU - Spigel, D. AU - Ishii, H. AU - Garassino, M. AU - Marinis, F. PY - 2018 DA - 2018// TI - Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30673-9 DO - 10.1016/S1470-2045(18)30673-9 ID - Barlesi2018 ER - TY - JOUR AU - Cohen, E. E. W. AU - Soulieres, D. AU - Tourneau, C. AU - Dinis, J. AU - Licitra, L. AU - Ahn, M. J. PY - 2019 DA - 2019// TI - Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study JO - Lancet VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)31999-8 DO - 10.1016/S0140-6736(18)31999-8 ID - Cohen2019 ER - TY - JOUR AU - Hellmann, M. D. AU - Nathanson, T. AU - Rizvi, H. AU - Creelan, B. C. AU - Sanchez-Vega, F. AU - Ahuja, A. PY - 2018 DA - 2018// TI - Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.03.018 DO - 10.1016/j.ccell.2018.03.018 ID - Hellmann2018 ER - TY - JOUR AU - Conforti, F. AU - Pala, L. AU - Bagnardi, V. AU - Pas, T. AU - Martinetti, M. AU - Viale, G. PY - 2018 DA - 2018// TI - Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30261-4 DO - 10.1016/S1470-2045(18)30261-4 ID - Conforti2018 ER - TY - JOUR AU - Ribas, A. AU - Dummer, R. AU - Puzanov, I. AU - VanderWalde, A. AU - Andtbacka, R. H. I. AU - Michielin, O. PY - 2018 DA - 2018// TI - oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy JO - Cell. VL - 174 UR - https://doi.org/10.1016/j.cell.2018.07.035 DO - 10.1016/j.cell.2018.07.035 ID - Ribas2018 ER - TY - JOUR AU - Carrero, I. AU - Liu, H. C. AU - Sikora, A. G. AU - Milosavljevic, A. PY - 2019 DA - 2019// TI - Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments JO - Oncogene. VL - 38 UR - https://doi.org/10.1038/s41388-018-0659-4 DO - 10.1038/s41388-018-0659-4 ID - Carrero2019 ER - TY - JOUR AU - Routy, B. AU - Chatelier, E. AU - Derosa, L. AU - Duong, C. P. M. AU - Alou, M. T. AU - Daillere, R. PY - 2018 DA - 2018// TI - Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan3706 DO - 10.1126/science.aan3706 ID - Routy2018 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. AU - Song, C. AU - Moreno, B. H. AU - Hu-Lieskovan, S. PY - 2017 DA - 2017// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell. VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.010 DO - 10.1016/j.cell.2017.01.010 ID - Hugo2017 ER - TY - JOUR AU - Segovia, M. AU - Russo, S. AU - Jeldres, M. AU - Mahmoud, Y. D. AU - Perez, V. AU - Duhalde, M. PY - 2019 DA - 2019// TI - Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation JO - Cancer Cell VL - 35 UR - https://doi.org/10.1016/j.ccell.2019.04.003 DO - 10.1016/j.ccell.2019.04.003 ID - Segovia2019 ER - TY - JOUR AU - Lee, H. H. AU - Wang, Y. N. AU - Xia, W. AU - Chen, C. H. AU - Rau, K. M. AU - Ye, L. PY - 2019 DA - 2019// TI - Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy JO - Cancer Cell VL - 36 UR - https://doi.org/10.1016/j.ccell.2019.06.008 DO - 10.1016/j.ccell.2019.06.008 ID - Lee2019 ER - TY - JOUR AU - Abdel-Rahman, O. PY - 2018 DA - 2018// TI - Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis JO - Clin Respir J VL - 12 UR - https://doi.org/10.1111/crj.12742 DO - 10.1111/crj.12742 ID - Abdel-Rahman2018 ER - TY - JOUR AU - Li, B. AU - Huang, X. AU - Fu, L. PY - 2018 DA - 2018// TI - Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis JO - Onco Targets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S156421 DO - 10.2147/OTT.S156421 ID - Li2018 ER - TY - JOUR AU - Lee, C. K. AU - Man, J. AU - Lord, S. AU - Cooper, W. AU - Links, M. AU - Gebski, V. PY - 2018 DA - 2018// TI - Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.4427 DO - 10.1001/jamaoncol.2017.4427 ID - Lee2018 ER - TY - JOUR AU - Gandhi, L. AU - Rodriguez-Abreu, D. AU - Gadgeel, S. AU - Esteban, E. AU - Felip, E. AU - Angelis, F. PY - 2018 DA - 2018// TI - Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801005 DO - 10.1056/NEJMoa1801005 ID - Gandhi2018 ER - TY - JOUR AU - Wu, Y. L. AU - Lu, S. AU - Cheng, Y. AU - Zhou, C. AU - Wang, J. AU - Mok, T. PY - 2019 DA - 2019// TI - Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.01.006 DO - 10.1016/j.jtho.2019.01.006 ID - Wu2019 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - PLoS Med VL - 6 UR - https://doi.org/10.1371/journal.pmed.1000097 DO - 10.1371/journal.pmed.1000097 ID - Moher2009 ER - TY - JOUR AU - Higgins, J. P. AU - Altman, D. G. AU - Gotzsche, P. C. AU - Juni, P. AU - Moher, D. AU - Oxman, A. D. PY - 2011 DA - 2011// TI - The Cochrane Collaboration's tool for assessing risk of bias in randomised trials JO - BMJ VL - 343 UR - https://doi.org/10.1136/bmj.d5928 DO - 10.1136/bmj.d5928 ID - Higgins2011 ER - TY - JOUR AU - Antonia, S. J. AU - Villegas, A. AU - Daniel, D. AU - Vicente, D. AU - Murakami, S. AU - Hui, R. PY - 2018 DA - 2018// TI - Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809697 DO - 10.1056/NEJMoa1809697 ID - Antonia2018 ER - TY - JOUR AU - Carbone, D. P. AU - Reck, M. AU - Paz-Ares, L. AU - Creelan, B. AU - Horn, L. AU - Steins, M. PY - 2017 DA - 2017// TI - First-line nivolumab in stage IV or recurrent non-small-cell lung cancer JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613493 DO - 10.1056/NEJMoa1613493 ID - Carbone2017 ER - TY - JOUR AU - Fehrenbacher, L. AU - Spira, A. AU - Ballinger, M. AU - Kowanetz, M. AU - Vansteenkiste, J. AU - Mazieres, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Mok, T. S. K. AU - Wu, Y. L. AU - Kudaba, I. AU - Kowalski, D. M. AU - Cho, B. C. AU - Turna, H. Z. PY - 2019 DA - 2019// TI - Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial JO - Lancet VL - 393 UR - https://doi.org/10.1016/S0140-6736(18)32409-7 DO - 10.1016/S0140-6736(18)32409-7 ID - Mok2019 ER - TY - JOUR AU - Reck, M. AU - Mok, T. S. K. AU - Nishio, M. AU - Jotte, R. M. AU - Cappuzzo, F. AU - Orlandi, F. PY - 2019 DA - 2019// TI - Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial JO - Lancet Respir Med VL - 7 UR - https://doi.org/10.1016/S2213-2600(19)30084-0 DO - 10.1016/S2213-2600(19)30084-0 ID - Reck2019 ER - TY - JOUR AU - Rittmeyer, A. AU - Barlesi, F. AU - Waterkamp, D. AU - Park, K. AU - Ciardiello, F. AU - Pawel, J. PY - 2017 DA - 2017// TI - Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial JO - Lancet VL - 389 UR - https://doi.org/10.1016/S0140-6736(16)32517-X DO - 10.1016/S0140-6736(16)32517-X ID - Rittmeyer2017 ER - TY - JOUR AU - West, H. AU - McCleod, M. AU - Hussein, M. AU - Morabito, A. AU - Rittmeyer, A. AU - Conter, H. J. PY - 2019 DA - 2019// TI - Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial JO - Lancet Oncology. VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30167-6 DO - 10.1016/S1470-2045(19)30167-6 ID - West2019 ER - TY - JOUR AU - Govindan, R. AU - Szczesna, A. AU - Ahn, M. J. AU - Schneider, C. P. AU - Gonzalez Mella, P. F. PY - 2017 DA - 2017// TI - Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.71.7629 DO - 10.1200/JCO.2016.71.7629 ID - Govindan2017 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crino, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature. VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Ng, T. L. AU - Liu, Y. AU - Dimou, A. AU - Patil, T. AU - Aisner, D. L. AU - Dong, Z. PY - 2019 DA - 2019// TI - Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer JO - Cancer. VL - 125 UR - https://doi.org/10.1002/cncr.31871 DO - 10.1002/cncr.31871 ID - Ng2019 ER - TY - JOUR AU - Lin, C. AU - Chen, X. AU - Li, M. AU - Liu, J. AU - Qi, X. AU - Yang, W. PY - 2015 DA - 2015// TI - Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma JO - Clinical Lung Cancer. VL - 16 UR - https://doi.org/10.1016/j.cllc.2015.02.002 DO - 10.1016/j.cllc.2015.02.002 ID - Lin2015 ER - TY - JOUR AU - Sorensen, S. F. AU - Zhou, W. AU - Dolled-Filhart, M. AU - Georgsen, J. B. AU - Wang, Z. AU - Emancipator, K. PY - 2016 DA - 2016// TI - PD-L1 Expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy JO - Transl Oncol VL - 9 UR - https://doi.org/10.1016/j.tranon.2016.01.003 DO - 10.1016/j.tranon.2016.01.003 ID - Sorensen2016 ER - TY - JOUR AU - Tokito, T. AU - Azuma, K. AU - Kawahara, A. AU - Ishii, H. AU - Yamada, K. AU - Matsuo, N. PY - 2016 DA - 2016// TI - Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy JO - Eur J Cancer VL - 55 UR - https://doi.org/10.1016/j.ejca.2015.11.020 DO - 10.1016/j.ejca.2015.11.020 ID - Tokito2016 ER - TY - JOUR AU - Kerdidani, D. AU - Magkouta, S. AU - Chouvardas, P. AU - Karavana, V. AU - Glynos, K. AU - Roumelioti, F. PY - 2018 DA - 2018// TI - Cigarette smoke-induced emphysema exhausts early cytotoxic CD8(+) T cell responses against nascent lung cancer cells JO - J Immunol VL - 201 UR - https://doi.org/10.4049/jimmunol.1700700 DO - 10.4049/jimmunol.1700700 ID - Kerdidani2018 ER - TY - JOUR AU - Zhao, F. AU - Xiao, C. AU - Evans, K. S. AU - Theivanthiran, T. AU - DeVito, N. AU - Holtzhausen, A. PY - 2018 DA - 2018// TI - Paracrine Wnt5a-beta-Catenin signaling triggers a metabolic program that drives dendritic cell tolerization JO - Immunity VL - 48 UR - https://doi.org/10.1016/j.immuni.2017.12.004 DO - 10.1016/j.immuni.2017.12.004 ID - Zhao2018 ER - TY - JOUR AU - Marti, L. C. AU - Pavon, L. AU - Severino, P. AU - Sibov, T. AU - Guilhen, D. AU - Moreira-Filho, C. A. PY - 2014 DA - 2014// TI - Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation JO - Mem Inst Oswaldo Cruz VL - 109 UR - https://doi.org/10.1590/0074-0276130252 DO - 10.1590/0074-0276130252 ID - Marti2014 ER - TY - JOUR AU - Argentiero, A. n. t. o. n. e. l. l. a. AU - De Summa, S. i. m. o. n. a. AU - Di Fonte, R. o. b. e. r. t. a. AU - Iacobazzi, R. o. s. a. M. a. r. i. a. AU - Porcelli, L. e. t. i. z. i. a. AU - Da Vià, M. a. t. t. e. o. AU - Brunetti, O. r. o. n. z. o. AU - Azzariti, A. m. a. l. i. a. AU - Silvestris, N. i. c. o. l. a. AU - Solimando, A. n. t. o. n. i. o. G. i. o. v. a. n. n. i. PY - 2019 DA - 2019// TI - Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study JO - Cancers VL - 11 UR - https://doi.org/10.3390/cancers11070942 DO - 10.3390/cancers11070942 ID - Argentiero2019 ER - TY - JOUR AU - Wang, G. Z. AU - Zhang, L. AU - Zhao, X. C. AU - Gao, S. H. AU - Qu, L. W. AU - Yu, H. PY - 2019 DA - 2019// TI - The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy JO - Nat Commun VL - 10 UR - https://doi.org/10.1038/s41467-019-08887-7 DO - 10.1038/s41467-019-08887-7 ID - Wang2019 ER - TY - JOUR AU - Gettinger, S. N. AU - Choi, J. AU - Mani, N. AU - Sanmamed, M. F. AU - Datar, I. AU - Sowell, R. PY - 2018 DA - 2018// TI - A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-05032-8 DO - 10.1038/s41467-018-05032-8 ID - Gettinger2018 ER - TY - JOUR AU - Inamura, K. AU - Yokouchi, Y. AU - Kobayashi, M. AU - Sakakibara, R. AU - Ninomiya, H. AU - Subat, S. PY - 2017 DA - 2017// TI - Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis JO - Lung Cancer VL - 103 UR - https://doi.org/10.1016/j.lungcan.2016.11.013 DO - 10.1016/j.lungcan.2016.11.013 ID - Inamura2017 ER - TY - JOUR AU - Leone, P. AU - Berardi, S. AU - Frassanito, M. A. AU - Ria, R. AU - Re, V. AU - Cicco, S. PY - 2015 DA - 2015// TI - Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing JO - Blood. VL - 126 UR - https://doi.org/10.1182/blood-2015-01-623975 DO - 10.1182/blood-2015-01-623975 ID - Leone2015 ER - TY - JOUR AU - Leone, P. AU - Lernia, G. AU - Solimando, A. G. AU - Cicco, S. AU - Saltarella, I. AU - Lamanuzzi, A. PY - 2019 DA - 2019// TI - Bone marrow endothelial cells sustain a tumor-specific CD8(+) T cell subset with suppressive function in myeloma patients JO - Oncoimmunology. VL - 8 UR - https://doi.org/10.1080/2162402X.2018.1486949 DO - 10.1080/2162402X.2018.1486949 ID - Leone2019 ER - TY - JOUR AU - McKaig, R. G. AU - Baric, R. S. AU - Olshan, A. F. PY - 1998 DA - 1998// TI - Human papillomavirus and head and neck cancer: epidemiology and molecular biology JO - Head Neck. VL - 20 UR - https://doi.org/3.0.CO;2-O DO - 3.0.CO;2-O ID - McKaig1998 ER - TY - JOUR AU - Singal, G. AU - Miller, P. G. AU - Agarwala, V. AU - Li, G. AU - Kaushik, G. AU - Backenroth, D. PY - 2019 DA - 2019// TI - Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database JO - JAMA. VL - 321 UR - https://doi.org/10.1001/jama.2019.3241 DO - 10.1001/jama.2019.3241 ID - Singal2019 ER - TY - JOUR AU - Igawa, S. AU - Sasaki, J. AU - Otani, S. AU - Shirasawa, M. AU - Niwa, H. AU - Kusuhara, S. PY - 2016 DA - 2016// TI - Smoking history as a predictor of pemetrexed monotherapy in patients with non-squamous non-small cell lung cancer JO - Oncology. VL - 91 UR - https://doi.org/10.1159/000446438 DO - 10.1159/000446438 ID - Igawa2016 ER - TY - JOUR AU - Fung, C. AU - Sesso, H. D. AU - Williams, A. M. AU - Kerns, S. L. AU - Monahan, P. AU - Abu Zaid, M. PY - 2017 DA - 2017// TI - Multi-institutional assessment of adverse health outcomes among north american testicular cancer survivors after modern cisplatin-based chemotherapy JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.3108 DO - 10.1200/JCO.2016.70.3108 ID - Fung2017 ER - TY - JOUR AU - Kelemen, L. E. AU - Warren, G. W. AU - Koziak, J. M. AU - Kobel, M. AU - Steed, H. PY - 2016 DA - 2016// TI - Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer JO - Gynecol Oncol VL - 140 UR - https://doi.org/10.1016/j.ygyno.2015.11.008 DO - 10.1016/j.ygyno.2015.11.008 ID - Kelemen2016 ER - TY - JOUR AU - Skillington, S. A. AU - Kallogjeri, D. AU - Lewis, J. S. AU - Piccirillo, J. F. PY - 2017 DA - 2017// TI - The role of adjuvant chemotherapy in surgically managed, p16-positive oropharyngeal squamous cell carcinoma JO - JAMA Otolaryngol Head Neck Surg VL - 143 UR - https://doi.org/10.1001/jamaoto.2016.3353 DO - 10.1001/jamaoto.2016.3353 ID - Skillington2017 ER - TY - JOUR AU - Ye, L. AU - Pu, C. AU - Tang, J. AU - Wang, Y. AU - Wang, C. AU - Qiu, Z. PY - 2019 DA - 2019// TI - Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis JO - Respir Res VL - 20 UR - https://doi.org/10.1186/s12931-019-1071-5 DO - 10.1186/s12931-019-1071-5 ID - Ye2019 ER - TY - JOUR AU - Peng, J. AU - Hamanishi, J. AU - Matsumura, N. AU - Abiko, K. AU - Murat, K. AU - Baba, T. PY - 2015 DA - 2015// TI - Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3098 DO - 10.1158/0008-5472.CAN-14-3098 ID - Peng2015 ER - TY - JOUR AU - Shin, J. AU - Chung, J. H. AU - Kim, S. H. AU - Lee, K. S. AU - Suh, K. J. AU - Lee, J. Y. PY - 2019 DA - 2019// TI - Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer JO - Cancer Res Treat VL - 51 UR - https://doi.org/10.4143/crt.2018.537 DO - 10.4143/crt.2018.537 ID - Shin2019 ER -